Refocusing ZymoGenetics Cuts Staff, Seeds Pipeline Of Private Startup Firm
This article was originally published in The Pink Sheet Daily
Executive Summary
In a deal that resembles a spin-out but is termed an arms-length transaction, ZymoGenetics transfers eight preclinical programs to Seattle Life Sciences for future considerations, including an equity stake.
You may also be interested in...
With No Competition, BMS Looks to Complete $885 Mil. Buy of ZymoGenetics
Bristol-Myers Squibb launched its $885-million tender offer for Seattle biotech ZymoGenetics Sept. 10, with two major shareholders representing more than a third of the biotech's shares already on board. The acquisition would give Bristol full rights to a mid-stage interferon treatment for hepatitis C that it currently shares with ZymoGenetics.
With No Competition, BMS Looks to Complete $885 Mil. Buy of ZymoGenetics
Bristol-Myers Squibb launched its $885-million tender offer for Seattle biotech ZymoGenetics Sept. 10, with two major shareholders representing more than a third of the biotech's shares already on board. The acquisition would give Bristol full rights to a mid-stage interferon treatment for hepatitis C that it currently shares with ZymoGenetics.
From HCV Partner To Acquirer, BMS Makes $885 M Offer for ZymoGenetics
Ever since its pure-play biopharma strategy went into effect, Bristol-Myers Squibb has preferred buying biotechs it knows well. Hepatitis C development partner ZymoGenetics is no exception.